|
CN113582889B
(zh)
|
2015-02-16 |
2024-09-20 |
昆士兰大学 |
磺酰脲和相关化合物及其用途
|
|
KR102701209B1
(ko)
|
2015-10-20 |
2024-08-29 |
매직 립, 인코포레이티드 |
3차원 공간에서 가상 객체들 선택
|
|
EP3436863B1
(en)
|
2016-03-31 |
2024-07-10 |
Magic Leap, Inc. |
Interactions with 3d virtual objects using poses and multiple-dof controllers
|
|
MY197636A
(en)
|
2017-01-23 |
2023-06-29 |
Genentech Inc |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
WO2019008025A1
(en)
|
2017-07-07 |
2019-01-10 |
Inflazome Limited |
NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
|
|
ES2949404T3
(es)
*
|
2017-07-24 |
2023-09-28 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
JP7412328B2
(ja)
|
2017-07-24 |
2024-01-12 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
WO2019034692A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
BR112020003014A2
(pt)
|
2017-08-15 |
2020-07-28 |
Inflazome Limited |
sulfonilureias e sulfoniltioureias como inibidores de vnlrp3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
WO2019079119A1
(en)
*
|
2017-10-17 |
2019-04-25 |
IFM Tre, Inc. |
SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
|
|
US12221434B2
(en)
|
2017-11-09 |
2025-02-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
CA3078195A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166628A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166632A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
EP3759090A1
(en)
*
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166633A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
EP3759089A1
(en)
*
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
MA52489A
(fr)
|
2018-05-04 |
2021-03-10 |
Inflazome Ltd |
Nouveaux composés
|
|
JP2021529186A
(ja)
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Ｎｌｒｐ調節剤
|
|
AU2019299444A1
(en)
|
2018-07-03 |
2021-01-14 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist
|
|
MA53170A
(fr)
|
2018-07-20 |
2021-05-26 |
F Hoffmann La Roche Sa |
Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1
|
|
MA53172A
(fr)
|
2018-07-20 |
2021-05-26 |
Hoffmann La Roche |
Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
|
|
SG11202101480XA
(en)
|
2018-08-15 |
2021-03-30 |
Inflazome Ltd |
Novel sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
WO2020086728A1
(en)
*
|
2018-10-24 |
2020-04-30 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
EP3880673B1
(en)
*
|
2018-11-13 |
2024-01-03 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
JP2022506898A
(ja)
*
|
2018-11-13 |
2022-01-17 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物
|
|
JP2022507505A
(ja)
*
|
2018-11-16 |
2022-01-18 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
WO2020154321A1
(en)
*
|
2019-01-22 |
2020-07-30 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN114761383A
(zh)
*
|
2019-06-12 |
2022-07-15 |
诺瑟拉有限公司 |
磺酰胺衍生物及其用途
|
|
WO2020254697A1
(en)
|
2019-06-21 |
2020-12-24 |
Ac Immune Sa |
Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
|
|
US12351564B2
(en)
|
2019-07-17 |
2025-07-08 |
Zomagen Biosciences Ltd |
NLRP3 modulators
|
|
KR20220064364A
(ko)
|
2019-07-17 |
2022-05-18 |
조마젠 바이오사이언시즈 엘티디 |
다발성 경화증(ms)의 치료를 위한 nlpr3 조절제로서의 n-((1,2,3,5,6,7-헥사하이드로-s-인다센-4-일)카바모일)-4,5,6,7-테트라하이드로벤조푸란-2-설폰아미드 유도체 및 관련 화합물
|
|
WO2021032588A1
(en)
|
2019-08-16 |
2021-02-25 |
Inflazome Limited |
Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
|
|
US20220289692A1
(en)
|
2019-09-06 |
2022-09-15 |
Inflazome Limited |
Nlrp3 inhibitors
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
CA3175729A1
(en)
|
2020-03-16 |
2021-09-23 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
US20230172933A1
(en)
*
|
2020-03-19 |
2023-06-08 |
Nanyang Technological University |
Use of a compound or composition comprising an inhibitor of nlrp1 inflammasome activation for the treatment of human airway inflammation
|
|
CN115279739B
(zh)
*
|
2020-03-27 |
2025-07-22 |
尼科治疗有限公司 |
取代哒嗪化合物
|
|
CN111419842A
(zh)
*
|
2020-04-24 |
2020-07-17 |
南方医科大学南方医院 |
炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
|
|
WO2021249337A1
(zh)
|
2020-06-11 |
2021-12-16 |
南京明德新药研发有限公司 |
二甲基亚磺酰亚胺衍生物
|
|
CA3178361A1
(en)
|
2020-06-19 |
2021-12-23 |
Emanuele Gabellieri |
Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
|
|
WO2022022646A1
(zh)
*
|
2020-07-29 |
2022-02-03 |
南京明德新药研发有限公司 |
含硒五元杂芳环化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
MX2023012795A
(es)
|
2021-04-28 |
2023-11-08 |
Astellas Pharma Inc |
Compuesto de triazina sustituida.
|
|
IL310264A
(en)
|
2021-07-21 |
2024-03-01 |
Nico Therapeutics Inc |
Annulated pyridazine compound
|
|
CN114213358A
(zh)
*
|
2021-12-22 |
2022-03-22 |
上海泰坦科技股份有限公司 |
一种2-溴-5-甲醛基噻唑的合成方法
|
|
JP2025502732A
(ja)
|
2021-12-22 |
2025-01-28 |
エーシー・イミューン・エス・アー |
ジヒドロオキサゾール誘導体化合物
|
|
KR20250036233A
(ko)
|
2022-07-14 |
2025-03-13 |
에이씨 이뮨 에스에이 |
Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체
|
|
WO2024023266A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
Novel compounds
|
|
CN120152974A
(zh)
|
2022-10-26 |
2025-06-13 |
天维生物制药有限公司 |
缩环哒嗪衍生物
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
AU2024238394A1
(en)
*
|
2023-03-17 |
2025-10-30 |
Ventus Therapeutics U.S., Inc. |
Amide derivatives for inhibiting nlrp3 and uses thereof
|
|
AR132817A1
(es)
|
2023-06-02 |
2025-07-30 |
Merck Sharp & Dohme Llc |
Heterociclos bicíclicos 5,6 insaturados útiles como inhibidores de la proteína receptora 3 similar a nod
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|